+612 9045 4394
 
CHECKOUT
$7.95 Delivery per order to Australia and New Zealand
100% Australian owned
Over a hundred thousand in-stock titles ready to ship
Cardiac Arrhythmias 2003 : Proceedings of the 8th International Workshop on Cardiac Arrhythmias - Antonio Raviele

Cardiac Arrhythmias 2003

Proceedings of the 8th International Workshop on Cardiac Arrhythmias

By: Antonio Raviele (Editor)

Hardcover Published: 10th October 2003
ISBN: 9788847002319
Number Of Pages: 921

Share This Book:

Hardcover

$220.74
or 4 easy payments of $55.19 with Learn more
Ships in 10 to 15 business days

Earn 441 Qantas Points
on this Book

The field of cardiac arrhythmias has been evolving so fast during the last years that scientific meetings are frequently necessary to present technological advances, to communicate results of relevant and innovative researches, to assess the impact of recently developed diagnostic and therapeutical tools, to discuss controversial aspects, and to reach a consensus on the most appropriate evaluation and management of specific problems. This is the main reason why in 1988 we started to organize a biannual International Workshop on Cardiac Arrhythmias. Since then many editions of the workshop have taken place and over the years the fame and popularity of the event have increased continuously. This book contains the Proceedings of the Eighth Edition of the Workshop th th held in Venice at the Fondazione Giorgio Cini from the 5 to the 8 of October 2003. During the meeting all the principal aspects of the different arrhythmias, from epidemiology to physiopathology, electrogenetic mechanisms, diagnosis, prognosis, treatment, pshycological implications and economic costs have been discussed among the numerous experts and participants.

Atrial Fibrillation: Clinical Aspects and Cardioversion
Sympathetic and Vagal Fibrillation: Do They Exist?p. 3
"Lone" Atrial Fibrillation in Athletes: A Consequence Of Long-Term Intensive Sport Practicep. 11
Predicting Atrial Fibrillation in Patients with Hypertension: Can We Do It?p. 23
What is the impact of Atrial Fibrillation on the Clinical Course of Hypertrophic Cardiomyopathy?p. 29
Atrial Fibrillation in Heart Failure: Prognostic Significance and Managementp. 37
Atrial Fibrillation After Cardiac Surgery: What's All the Fuss About?p. 43
"Pill in the Pocket": How Effective and Safe Is this Strategy for Treatment of Recurrences of Atrial Fibrillation?p. 51
Cardioversion of Recent Onset Atrial Fibrillation: Which Drug to Prefer in the Individual Patient?p. 57
Pretreatment with Antiarrhythmic Drugs: Is It Useful to Avoid Immediate and Early Postcardioversion Recurrences?p. 65
Is Echocardiography Useful to Predict Successful Cardioversion of Atrial Fibrillation and Long-Term Maintenance of Sinus Rhythm?p. 71
Does the Policy of Repeated Early Cardioversion for Recurrences of Atrial Fibrillation Work?p. 79
Medical Treatment of Atrial Fibrillation: Rhythm Control and Rate Control
Which Is the Ideal Drug for Chronic Prophylaxis of Atrial Fibrillation?p. 85
ACE Inhibitors and Angiotensin Receptor Blockers: a New Effective Non-Conventional Approach to Prevent Atrial Fibrillationp. 93
Rate Control of Atrial Fibrillation: By How Much Should the Ventricular Rate be Lowered?p. 99
Ablate and Pace: Is This Still a Valid Option?p. 107
Transvascular Parasympathetic Stimulation for Ventricular Rate Control During Atrial Fibrillation: A Bionic Approachp. 117
Management of Atrial Fibrillation: Is it Already Time to Update the Recent ACC/AHA/ESC Guidelines?p. 127
Atrial Fibrillation: Electrical Therapy, Transcatheter and Surgical Ablation
Atrial Fibrillation Suppression: What Role Does It Have?p. 137
Dual-chamber ICDs: How Effective and Safe Are They in the Treatment of Atrial Tachyarrhythmias?p. 141
Ablation of Atrial Fibrillation: Are We Still "Learning While Burning"?p. 149
Ablation of Atrial Fibrillation: Is a Cure at Hand?p. 159
Atrial Fibrillation: Anatomical Guidance Is Superior to Electrophysiological Guidance for Ablationp. 167
Atrial Fibrillation: Catheter Laser Balloon Ablationp. 173
Isolation of Pulmonary Veins Using Cryothermal Technologiesp. 177
Ablation of Atrial Fibrillation by Radiofrequency: Circular Energy Deliveryp. 189
Catheter Ablation of Atrial Fibrillation: What Are the Risks and Complications and How Do We Avoid Them?p. 195
Risk Stratification and Prevention of Thromboembolism: What Is the Role of Intracardiac Echocardiography?p. 205
Radiofrequency and Microwave Ablation of Atrial Fibrillation During Open Heart Surgery: What Are the Long-Term Results?p. 215
Minimally Invasive Surgical Approach to Radiofrequency Ablation of Atrial Fibrillation: Is the Game Worth the Candle?p. 221
Atrial Fibrillation: Prevention of Thromboembolic Complications
What Is the Best Practical Scheme for Initiating Oral Anticoagulant Treatment in Outpatients with Atrial Fibrillation?p. 231
How Intense Should Anticoagulation Be at the Time of Cardioversion to Reduce the Risk of Thromboembolism?p. 235
Warfarin Underuse for Nonvalvular Atrial Fibrillation: How to Adjust Our Aims?p. 241
Supraventricular Tachyarrhythmias: Diagnosis and Treatment
Palpitations of Unknown Origin: How Frequent Are Supraventricular Arrhythmias?p. 251
Acute Termination of Atrial Flutter: Class III Drugs or Transesophageal Pacing?p. 257
Atrial Flutter Induced by Class IC Drugs/Amiodarone: What Are the Long-term Results of Cavo-tricuspidal Isthmus Ablation?p. 263
Non-Isthmus-Dependent Atrial Flutter: How to Locate and Ablate the Re-entry Circuitp. 271
Complex Supraventricular Tachycardia Ablation: What Is the Role of Alternative Technology?p. 285
Late Atrial Tachyarrhythmias After Repair of Congenital Heart Disease What is the Mechanism and How Can They Be Localized and Ablated?p. 293
Late Atrial Arrhythmias as a Complication After Valvular Heart Surgery: Is There A Place for Prevention?p. 301
Ventricular Arrhythmias and Sudden Death
Coffee Enhances Sympathetic Activity and Induces Cardiac Arrhythmias: True or False?p. 309
Is the Cause of Arrhythmogenic Right Ventricular Cardiomyopathy Congenital or Acquired?p. 313
Is ICD Implantation Useful in Patients with Arrhythmogenic Right-ventricular Cardiomyopathy?p. 323
What is the Prevalence, Incidence and Prognostic Value of Brugada-type Electrocardiogram in the General Population?p. 331
Brugada Syndrome or Brugada Mimicry?p. 335
Ventricular Tachycardia or Conduction Disease: What Is the Mechanism of Death in Brugada Syndrome?p. 339
Idiopathic Ventricular Tachycardia: Is Radiofrequency Ablation the First Line Therapy?p. 347
Ventricular Tachycardia from the Aortic Cusps: Localization and Ablationp. 357
Extreme Left Vetricular Hypertrophy: An Indicator of Increased Risk of Sudden Death in Hypertrophic Cardiomyopathyp. 371
Does a Maximum Left Ventricular Thickness Greater than 30 mm Identify Patients with Hypertrophic Cardiomyopathy at Risk of Sudden Death?p. 375
Drug-Induced Torsade de Pointes. Role of Genetic Factorsp. 379
Identifying Patients at High Risk for Sudden Cardiac Death: Is Low Ejection Fraction Alone Enough, or Do We Need Additional Testing?p. 387
What Is The Prognostic Value of Non-Sustained Ventricular Tachycardia in Patients Without Severely Depressed Ejection Fraction After Myocardial Infarction?p. 397
Mechanical/Surgical Revascularization in Patients with Ventricular Fibrillation and Coronary Artery Disease: Is It Enough, or Do We Also Need an Implantable Cardioverter Defibrillator?p. 405
Surgical Revascularization in Patients with "Ischemia-related" Ventricular Fibrillation: Is It Sufficient to Prevent Sudden Death?p. 413
New-onset Ventricular Tachyarrhythmias After Cardiac Surgery: Significance and Treatmentp. 415
Electrophysiologically Guided Antiarrhythmic Surgery for Treatment of Frequently Recurrent Ventricular Tachycardia: What Role Does It Have Today?p. 419
Heart Transplantation in Frequently Recurrent Drug-Refractory Tachyarrhythmias: is it Worthwhile?p. 427
Ablation of Unstable Ventricular Tachycardiap. 433
Ablation of Ventricular Tachycardia: Can the Current Results be Improved Using Intracardiac Echocardiography?p. 451
Implantable Cardioverter Defibrillator: Practical Aspects, Indications and Cost-Effectiveness
Left Ventricular Dysfunction and Electrophysiologic Study in the Primary and Secondary ICD Trialsp. 463
New Evidence from the Secondary Endpoints of the MADIT II Studyp. 469
The Real Economic Impact of the MADIT-II Study on the European Medical Communityp. 475
Post-infarction Patients with Left Ventricular Ejection Fraction of 30%-40%, Non-sustained Ventricular Tachycardia, and without Inducible Tachyarrhythmias: Is ICD Therapy Necessary?p. 481
Secondary Prevention of Sudden Death in Post-Infarction Patients: When is ICD Implantation Really Cost-Effective?p. 489
Primary Prevention of Sudden Death in Post-Infarction Patients: When ICD Implantation is Really Cost-effectivep. 497
Cost-Effectiveness of ICD Implantation in Clinical Settings Different From Ischemic Heart Disease: What Do We Know?p. 505
Expanding ICD Indications: Can We Afford It?p. 511
Waveform Flexibility: The Present and Future Solution for Clinically Effective Defibrillationp. 519
Lessons from the Lower Energy Safety Study (LESS): Is One Ventricular Fibrillation Induction Adequate for ICD Implant?p. 527
Inappropriate Defibrillator Therapies: Do Dual-chamber Devices Really Provide a Remedy?p. 535
Should Antiarrhythmic Drugs Be Administered After First Appropriate ICD Shock, and If So, Which Ones?p. 541
Quality of Life in Patients with ICD: Is It Improved or Worsened?p. 547
Out-of-Hospitals Cardiac Arrest and Public Access Defibrillation
Public Use of AEDs in Europe: Where Are We Now and Where Are We Going?p. 555
Use of AED by Lay People in Patients with Out-of-Hospital Cardiac Arrest: How Does It Impact Survival?p. 563
In-Hospital Cardiac Arrest: Are We Well Enough Equipped and Prepared to Face It?p. 569
Mild Therapeutic Hypothermia for Treatment of Cardiac Arrest: Current Results and Future Perspectivesp. 579
Syncope: Current Evaluation and Management
Distinguishing Syncope From Seizures: How Useful is the Clinical History?p. 589
Diagnosis of Neurally Mediated Syncope: Might Use of the Implantable Loop Recorder Replace the Tilt-table Test? A Positive Viewp. 595
Unexplained Syncope: Can We Predict the Outcome of Prolonged Monitoring with the Implantable Loop Recorder?p. 599
Patients with Structural Heart Disease, Syncope of Unknown Origin and Suspected Ventricular Tachycardia: ICD Implantation or "Wait and See" Strategy?p. 607
Vasovagal Syncope, Orthostatic Hypotension and Postural Orthostatic Tachycardia Syndrome: Is There a Connection?p. 615
Water Drinking to Prevent Orthostatic Hypotension and Neurally Mediated Syncope: Mechanisms and Benefitsp. 625
Physical Counterpressure Maneuvers to Prevent and Abort Vasovagal Syncope: A Novel Effective Treatment?p. 633
Isometric Arm Contraction at the Onset of Prodromal Symptoms: a New First-line Treatment for Vasovagal Syncope?p. 641
To Pace or not to Pace for Neurally Mediated Syncope: Do We Know the Answer? A Positive Viewp. 651
To Pace or Not to Pace for Neurally Mediated Syncope: Do We Know the Answer? A Negative Viewp. 655
Patient-Activated Implantable Drug Pump for Treatment of Vasovagal Syncope: Is It Time for Clinical Use?p. 659
Sick Sinus Syndrome: Clinical Aspects and Pacing Issues
Genetics of Sinus Node Diseasep. 667
Sleep Apnea: New Insightsp. 679
Remodeling of Sinus Node Function Produced by Supraventricular Tachyarrhythmias: What Are the Clinical Implications?p. 685
Drug-Induced Bradycardia: When Is a Pacemaker Warranted?p. 691
Permanent Pacing Treatment: Conventional DDDR, Antitachycardia Pacing or Atrial Defibrillator?p. 697
Hemodynamics and Cardiac Pacing
Hemodynamic Assessment with Implantable Pacemakers: How Feasible and Reliable Is It?p. 705
Hemodynamic Sensors: Their Impact in Clinical Practicep. 713
Haemodynamic Pacing: When Is It Selectively Indicated?p. 719
Can Hemodynamic Sensors Ensure Physiological Rate Control?p. 725
Transvalvular Impedance: Does It Allow Automatic Capture Detection?p. 733
What Are the Keys to Hemodynamic Improvement in Heart Failure Patients?p. 741
Atrioventricular Delay in Heart Failure Patients: How to Manage Itp. 745
Cardiac Resynchronisation and Haemodynamic Monitoring: the Living-CHF Studyp. 753
Heart Failure Therapy Driven by Implantable Sensors: What May We Expect?p. 759
Cardiac Resynchronization Therapy: Mechanisms, Technical and Clinical Aspects
Reverse Structural and Contractile Remodeling without Reverse Electrical Remodeling by Biventricular and Right Ventricular Apex Pacing in Dogs with Chronic AV Blockp. 767
How Are Perfusion and Adrenergic Innervation of the Left Ventricle Affected in Paced Patients?p. 777
Cardiac Resynchronization Therapy: The Low Voltage Road or the High Voltage Road?p. 785
Cardiac Resynchronization Therapy: What Are the Benefits of Digital Pacemakers?p. 793
Cardiac Resynchronization Therapy: What Device Data Do We Need for Optimal Patient Treatment?p. 799
How to Identify Patients Most Likely to Respond to Cardiac Resynchronization Therapyp. 805
Upgrading from Right Ventricular Apical Pacing to Biventricular Pacingp. 815
Cardiac Resynchronisation Therapy in Patients with Atrial Fibrillation: Are Results as Good as in Patients with Sinus Rhythm?p. 823
Patients with Heart Failure and Right Bundle Branch Block or Nonspecific Intraventricular Conduction Disturbances Can They Benefit from Cardiac Resynchronization Therapy?p. 829
Which Left Ventricular Stimulation Site Is Best for Cardiac Resynchronisation Therapy?p. 837
Permanent His Bundle Pacing: A Good Unconventional Mode of Right Ventricular Pacing?p. 843
Cardiac Resynchronization Therapy: Is Atrial Resynchronization Important with Biventricular Pacing?p. 851
Impact of Cardiac Resynchronization Therapy on Mortality: What Do We Expect from Ongoing Trials?p. 857
Companion Study: Rationalep. 861
Pharmacological Therapy in Companion Study: Compliance and Dosagep. 865
The Lesson from the Companion Study: How Large Is the Patient Population That May Benefit?p. 877
Pacemaker/ICD Complications: Detection and Management
How to Detect and Manage Pacemaker/ICD Failure and Infectionsp. 885
Pacemaker/ICD Lead Extraction Using the Excimer Laser Sheath: What Are the Advantages and What Are the Risks?p. 897
How to Detect and Treat superior Vena Cava Obstruction Caused by Multiple Pacing/ICD Leads?p. 903
Lead-Related Thrombi in Patients with Pacemaker/ICD: What Is the Prevalence, Clinical Significance, and Recommended Management?p. 909
Effects of Electromagnetic Interference on Implanted Cardiac Devicesp. 911
Subject Indexp. 919
Table of Contents provided by Rittenhouse. All Rights Reserved.

ISBN: 9788847002319
ISBN-10: 8847002311
Audience: General
Format: Hardcover
Language: English
Number Of Pages: 921
Published: 10th October 2003
Publisher: Springer Verlag
Country of Publication: IT
Dimensions (cm): 23.37 x 15.49  x 5.08
Weight (kg): 1.43

Earn 441 Qantas Points
on this Book

This product is categorised by